author-photo

Giuseppe Saglio

University of Turin

831

Papers

35885

Citations

Citation Trend

Filter By

Papers (594) Sort By

Journal Conference Others

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (2)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (22)
Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL

2021
Show All
- Source
- Cite
- Save
Citations (0)
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (1)
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A “Campus CML” Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Leukemia, (2021), 35, 2, (440-453), 10.1038/s41375-020-01111-2)

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic

2021 Applied Sciences
Show All
- Source
- Cite
- Save
Citations (1)
The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)